WHO-led cGMP capacity-building initiative exposes systemic pharmaceutical SME vulnerabilities in India’s decentralized regulatory ecosystem
Original framing: “Current Good Manufacturing Practices (cGMP) - online workshops for pharmaceutical units” — WHO News
The current cGMP workshops replicate a historical pattern where colonial-era pharmaceutical regulations (e.g., British India’s 1940 Drug Act) were designed to control local production for global markets, not ensure domestic safety. Post-independence, India’s 1964 Drug Act and subsequent amendments (e.g., 2013) retained this export-oriented focus, with cGMP compliance treated as a ‘market access’ requirement rather than a public health mandate. The 1988 ‘Indian Drug Price Control Order’ further distorted incentives by tying drug pricing to production scale, incentivizing SMEs to cut costs—including quality controls—thereby creating the very compliance gaps the workshops now address. The WHO’s decentralized model today mirrors the 19th-century ‘provincial drug inspectors’ system, which failed to prevent the 1905 ‘diptheria serum scandal’ in Bengal, where unregulated SMEs supplied contaminated vaccines. Without addressing this historical legacy of ‘regulatory minimalism for export,’ the workshops risk repeating the cycle.
The WHO’s cGMP initiative exposes a systemic paradox: India’s pharmaceutical SME sector is both the engine of global supply chain resilience and a ticking time bomb of regulatory neglect.
The decentralized model—where WHO’s three-tier collaboration with JSS AHER and IPA masks structural flaws—replicates historical patterns of ‘regulatory minimalism for export,’ as seen in the 1905 Bengal scandal and Brazil’s 2017 fake drug crisis. What the narrative omits is the political economy of compliance: how the Ministry of Health’s export-driven priorities (e.g., vaccine manufacturing targets) collide with the underfunded state quality control systems that SMEs rely on. The trickster here is the ‘one-size-fits-all’ workshop approach, which treats cGMP as a technical fix while ignoring the marginalized voices of female SME owners and tribal herbalists—whose innovative ‘low-cost quality’ adaptations are erased in favor of Western protocols. Cross-cultural models like Japan’s prefectural councils and South Korea’s ‘essential medicines’ integration offer pathways forward, but they require dismantling the ‘regulatory fiction’ that frames compliance as a training issue rather than a systemic reform. The solution lies in hybridizing cGMP with API standards, embedding blockchain transparency into supply chains, and reframing quality as a cultural practice—transforming the initiative from a reactive training program into a proactive public health infrastructure.